Loading…
Gossamer Bio, Inc. is projected to rise to $0.2688 by 2027, a +23% move from its current price of $0.2179. GOSS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.2046 | $0.2179 | $0.2321 | 0.00% |
| May 30 | $0.1993 | $0.2179 | $0.2382 | -0.01% |
| May 31 | $0.1953 | $0.2179 | $0.243 | -0.01% |
| Jun 1 | $0.1921 | $0.2179 | $0.2471 | -0.01% |
| Jun 2 | $0.1892 | $0.2179 | $0.2508 | -0.02% |
| Jun 3 | $0.1867 | $0.2179 | $0.2542 | -0.02% |
| Jun 4 | $0.1844 | $0.2178 | $0.2574 | -0.02% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.1844 | $0.2178 | $0.2574 | -0.02% |
| Week 2 | $0.172 | $0.2178 | $0.2757 | -0.05% |
| Week 3 | $0.1631 | $0.2177 | $0.2906 | -0.07% |
| Week 4 | $0.156 | $0.2177 | $0.3038 | -0.10% |
| Week 5 | $0.1499 | $0.2176 | $0.316 | -0.12% |
| Week 6 | $0.1446 | $0.2176 | $0.3273 | -0.14% |
| Week 7 | $0.1399 | $0.2175 | $0.3381 | -0.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small-molecule inhibitor targeting PDGFR, CSF1R, and c-KIT, which is in Phase 3 clinical trial for the treatment of PAH.
Gossamer Bio has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc.
in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc. trades under the symbol GOSS and operates in the Healthcare sector. The current price is $0.2101. The company has a market cap of $49.31M and ranks 4603 by market capitalization.
The long-range forecast indicates potential upside in the years ahead, with the 2050 average price projected at $1.12 and a max of $2.57, corresponding to an estimated ROI of 432.2%. In the near term, the stock remains subject to its current price dynamics.
A major floor 86.5% below — a decisive break under it would weaken the trend.
The nearest floor, 11.4% below — buyers have tended to step in here.
The nearest ceiling, 107.0% above — a clean break opens room to run.
A major ceiling 1217.1% above — clearing it would confirm fresh momentum.
Key GOSS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GOSS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2128 | Buy | $0.2209 | Sell |
| MA 10 | $0.247 | Sell | $0.2435 | Sell |
| MA 20 | $0.2972 | Sell | $0.2842 | Sell |
| MA 50 | $0.3504 | Sell | $0.4918 | Sell |
| MA 100 | $1.09 | Sell | $0.9529 | Sell |
| MA 200 | $1.93 | Sell | $1.38 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.24 | Neutral |
| Stoch RSI (14) | 50.58 | Neutral |
| CCI (20) | -84.57 | Neutral |
| Williams %R (14) | -83.44 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -33.33 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 16.56 | Buy |
| TRIX (15) | -1.75 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 22.60 | Buy |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.20 | Buy |
| ADX (14) | 34.86 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL. The RSI14 is 30, and the stock’s near-term momentum sits near the lower end of typical ranges. The measured moving averages place the price well below key levels, with a SMA50 of $0.3595 and a SMA200 of $1.94.
Support is identified at $0.193 and resistance at $0.451. The 30-day price range spans from $0.1357 to $0.3253, highlighting recent volatility within a tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.193 | $0.2179 | $0.3544 | 0% | Neutral | |
| $0.1934 | $0.2688 | $0.4041 | +23% | Bullish | |
| $0.2544 | $0.3752 | $0.5998 | +72% | Bullish | |
| $0.2525 | $0.3919 | $0.6569 | +80% | Bullish | |
| $0.2201 | $0.358 | $0.6241 | +64% | Bullish | |
| $0.2288 | $0.3888 | $0.7012 | +78% | Bullish | |
| $0.1777 | $0.315 | $0.5855 | +45% | Bullish | |
| $0.1805 | $0.3332 | $0.6363 | +53% | Bullish | |
| $0.271 | $0.5202 | $1.02 | +139% | Bullish | |
| $0.2708 | $0.5403 | $1.08 | +148% | Bullish | |
| $0.2475 | $0.55 | $1.21 | +152% | Bullish | |
| $0.5871 | $1.30 | $3.00 | +499% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.193 | $0.2179 | $0.2554 | +0.00% |
| June 2026 | $0.1688 | $0.2024 | $0.2515 | -7.12% |
| July 2026 | $0.1781 | $0.2172 | $0.2768 | +7.33% |
| August 2026 | $0.1819 | $0.2248 | $0.2921 | +3.48% |
| September 2026 | $0.1737 | $0.2171 | $0.2865 | -3.40% |
| October 2026 | $0.1837 | $0.2319 | $0.3103 | +6.79% |
| November 2026 | $0.2031 | $0.2588 | $0.3506 | +11.62% |
| December 2026 | $0.2013 | $0.2587 | $0.3544 | -0.05% |
Click any year to see its month-by-month GOSS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GOSS price prediction for 2026 points to an average of $0.2179 (low $0.193, high $0.3544) — a potential gain of 0% on today's $0.2179. A consolidation phase looks the most probable path here.
In 2027, GOSS is projected to trade between $0.1934 and $0.4041, averaging $0.2688 — a potential gain of +23% from today's $0.2179. That is up +23% on the projected 2026 average. Momentum favours further upside here.
Gossamer Bio, Inc.'s 2028 outlook centres on $0.3752, within a $0.2544 to $0.5998 range. That is up +40% on the projected 2027 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, GOSS could reach as high as $0.6569, with a base case around $0.3919 and support toward $0.2525 — roughly +80% from $0.2179. Momentum favours further upside here.
Expect GOSS to range from $0.2201 to $0.6241 through 2030. The $0.358 average target implies a +64% move from current prices. That is -9% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
The GOSS price prediction for 2031 points to an average of $0.3888 (low $0.2288, high $0.7012) — a potential gain of +78% on today's $0.2179. Momentum favours further upside here.
In 2032, GOSS is projected to trade between $0.1777 and $0.5855, averaging $0.315 — a potential gain of +45% from today's $0.2179. That is -19% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
Gossamer Bio, Inc.'s 2033 outlook centres on $0.3332, within a $0.1805 to $0.6363 range. That is up +6% on the projected 2032 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2034, GOSS could reach as high as $1.02, with a base case around $0.5202 and support toward $0.271 — roughly +139% from $0.2179. Buyers look set to stay in control over this stretch.
Expect GOSS to range from $0.2708 to $1.08 through 2035. The $0.5403 average target implies a +148% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The GOSS price prediction for 2040 points to an average of $0.55 (low $0.2475, high $1.21) — a potential gain of +152% on today's $0.2179. Buyers look set to stay in control over this stretch.
In 2050, GOSS is projected to trade between $0.5871 and $3.00, averaging $1.30 — a potential gain of +499% from today's $0.2179. That is up +137% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GOSS today (≈ 4,589.261129 GOSS) could be worth
$5,987
+$4,987 (+499%) by 2050 · US Dollar
Based on the average projected GOSS price of $1.3 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GOSSwould be worth at today's price.
$1,000 invested in GOSS on May 27, 2025 (≈ 892.857139 GOSS) would be worth
$194.55
-$805.45 (-80.5%) today · 0.19× · US Dollar
Based on a GOSS entry price of $1.12 vs. today's $0.2179.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.215 | $1,013.49 | +1.3% |
| 1 month ago | $0.349 | $624.36 | -37.6% |
| 3 months ago | $0.402 | $542.04 | -45.8% |
| 6 months ago | $3.34 | $65.24 | -93.5% |
| 1 year ago | $1.12 | $194.55 | -80.5% |
| All time (5.0y) ago | $8.58 | $25.4 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GOSS forecast.
Our base-case forecast reaches $0.44 around 2034.
Implied market cap at $0.44: $103.27M
The multi-year forecast shows a bullish trajectory beginning later in the horizon, with notable upside through 2050. The 2026 forecast presents a min of $0.193, an average of $0.2101, and a max of $0.3329 (ROI 0, sentiment NEUTRAL). From 2027 onward, the model projects rising averages and positive ROIs, including 2027 at an average of $0.247 with ROI 17.6 and 2028 at an average of $0.3465 with ROI 64.9.
The uptrend persists through 2029 (average $0.3613, ROI 72), 2030 (average $0.3319, ROI 58), 2031 (average $0.3559, ROI 69.4), 2032 (average $0.2825, ROI 34.5), 2033 (average $0.2976, ROI 41.7), 2034 (average $0.4567, ROI 117.4), and 2035 (average $0.4714, ROI 124.4). The forecast continues to 2040 (average $0.4733, ROI 125.3) and culminates in 2050 with an average of $1.12, a max of $2.57, and ROI of 432.2, all labeled as BULLISH. These projections imply meaningful upside over the longer term, contingent on market factors and outcomes, and should be viewed as estimates rather than guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $0.3319, with a min of $0.2039 and a max of $0.5789, and a forecasted ROI of 58%. The sentiment is BULLISH.
The forecast spans multiple years with a shift from Neutral in 2026–2027 to BULLISH from 2028 onward, noting an average price of $0.3319 in 2030 and a potential 2050 average of $1.12 with a max of $2.57 and ROI 432.2. These are estimates and not guarantees.
The long-term forecast includes a 2050 average price of $1.12 and a 2050 max of $2.57, indicating potential to exceed $1 in the horizon, but these are not guaranteed.
The 30-day range is $0.1357–$0.3253, with RSI 14 at 30. The SMA50 is $0.3595 and the SMA200 is $1.94. Support is at $0.193 and resistance at $0.451. The current price is $0.2101.
Market cap is $49.31M and the stock ranks 4603 by market capitalization.
Gossamer Bio, Inc. Community Discussion
0Share your Gossamer Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.